TEAM is live. Here’s what an administrator actually does about it.
Update — July 31, 2026: CMS finalized CJR-X (CMS-1849-F): the episode logic below goes nationwide from January 2028 for most IPPS hospitals — hip, knee, and ankle, 90-day episodes (TEAM participants and Maryland excepted). CJR-X, like TEAM, makes the hospital the accountable party, not the ASC. If the hospitals your surgeons operate with aren’t in a TEAM CBSA, CJR-X is their version of this mandate from 2028; the playbook in this post is the same muscle, on a longer runway.
The debate about whether value-based joint replacement would arrive is over. TEAM — CMS’s mandatory episode model — is live, and for the facilities inside it, every lower-extremity joint replacement now carries a 30-day episode window in which cost, complications, and outcomes are scored against a peer curve. There is no opt-in and no sitting out: the reconciliation math happens whether or not anyone in the building is watching it.
The administrator’s real problem
Most centers experience the mandate as paperwork. The actual event is financial: your episodes are being priced against your region’s, and the difference between the right side and the wrong side of that curve is money the center either keeps or returns. Two drivers dominate the spread:
- Revisions and complications. About one in five (19%) primary total knee replacement patients were not satisfied with the outcome in a 1,703-case Ontario study, and a complication requiring readmission was one of the strongest predictors (Bourne et al., Clin Orthop Relat Res 2010; PMID 19844772). Every complication and readmission inside the window counts in the episode.
- What happens after discharge. The window doesn’t close at the door. Readmissions, ED visits, and slow recoveries in the 30 days at home land on your score.
The four-item checklist
- Know your curve position. Pull your episode spend and revision rate against regional benchmarks. If you can’t produce this number in a week, that’s the first fix.
- Make personalization a line item, not a philosophy. Patient-specific planning and implant fit exist today and attack the dissatisfaction driver directly. Price it per case against what a single revision costs you inside the window.
- Instrument recovery. If the 30 days at home are invisible to you, you are being scored on something you can’t see. Remote tracking (RTM) both closes that gap and reimburses — though not to a practitioner receiving the global surgical payment, and only one practitioner can hold a given patient’s monthly slot.
- Capture outcomes registry-grade. AJRR + PROMs, on every case — because under two-sided risk, an outcome you can’t prove is an outcome you don’t get paid for.
Where MSKvalue fits
MSKvalue lays out exactly this stack — personalized planning, outcome capture, monitored recovery, and the documentation behind billing — as one accountable episode rather than a pile of point tools. Registry abstraction and the RTM record are in design.
Start the conversation →Not clinical, legal, or financial advice. MSKvalue assembles independent best-of-class products with the American Joint Replacement Registry as the outcomes backbone.